US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kyntra Bio Inc

7.10

-0.5100-6.70%

Post-market: 7.100.00000.00%19:30 EDT

Volume:38.62K

Turnover:281.95K

Market Cap:28.72M

PE:0.16

High:7.75

Open:7.73

Low:7.05

Close:7.61

52wk High:12.58

52wk Low:6.32

Shares:4.05M

Float Shares:3.56M

Volume Ratio:1.31

T/O Rate:1.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):45.27

EPS(LYR):45.37

ROE:--

ROA:-22.50%

PB:-0.95

PE(LYR):0.16

Loading ...

Overview Company News Filings

Kyntra Bio initiated with a Buy at Lake Street

NASDAQ Trade Halt Volatility Trading Pause at 01:23 Pm

Kyntra Bio Price Target Maintained with a $43.00/Share by HC Wainwright & Co.

Kyntra Bio Cuts Royalty Payments to NQ Project Phoebus for Accelerated Upfront Payment

MT Newswires Live

Kyntra Bio Says FibroGen Europe Unit Settles Bankruptcy Obligations for About $0.1 Million

Kyntra Bio cuts max royalty cap to $65M from $125M, pays $42.6M upfront

Kyntra Bio, - Reduces Royalty Financing Payment Cap to $65 Mln from $125 Mln

THOMSON REUTERS

Kyntra Bio, - Cash Runway Expected into Fourth Quarter of 2027

THOMSON REUTERS

Kyntra Bio, - Pro Forma Cash, Equivalents, Investments, Receivables $53.10 Mln as of June 30, 2026

THOMSON REUTERS

Kyntra Bio Prepays USD 42.6 Million Under Amended Royalty Financing Deal

Press Release: Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation

Oppenheimer Keeps Their Buy Rating on Kyntra Bio (KYNB)

Analysts Offer Insights on Healthcare Companies: Kyntra Bio (KYNB) and Minerva Neurosciences (NERV)

Kyntra Bio, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Kyntra Bio Posts Investor Presentation Highlighting FG-3246/fg-3180 Phase 2 Program in Prostate Cancer

Kyntra Bio Q2 EPS $2.96, Sales $(1.474M) Miss $2.007M Estimate

Benzinga Earnings

Kyntra Bio Q2 FY26 Returns to Profit at $12 Million; Revenue Turns to $(1.5) Million

Kyntra Bio Inc Q2 Net Income from Cont Ops USD 11.974 Million

Press Release: Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Kyntra Bio, Inc. Expected to Post a Loss of $3.18 a Share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/KYNB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYNB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","market":"US","secType":"STK","nameCN":"Kyntra Bio Inc","latestPrice":7.1,"timestamp":1789675200000,"preClose":7.61,"halted":0,"volume":38618,"hourTrading":{"tag":"盘后","latestPrice":7.1,"preClose":7.1,"latestTime":"19:30 EDT","volume":7,"amount":49.7,"timestamp":1789687802679,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.06701708278580823,"floatShares":3561200,"shares":4045445,"eps":45.266125,"marketStatus":"Closed","change":-0.51,"latestTime":"09-17 16:00:00 EDT","open":7.73,"high":7.7501,"low":7.05,"amount":281948.9907612,"amplitude":0.091997,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":45.266125,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":5,"adr":0,"listingDate":1415941200000,"exchange":"NASDAQ","adjPreClose":7.61,"postHourTrading":{"tag":"盘后","latestPrice":7.1,"preClose":7.1,"latestTime":"19:30 EDT","volume":7,"amount":49.7,"timestamp":1789687802679,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.31202},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","floatShares":3561200,"roa":"-22.50%","roe":"--","lyrEps":45.371456,"volumeRatio":1.31202,"shares":4045445,"dividePrice":0,"high":7.7501,"amplitude":0.091997,"preClose":7.61,"low":7.05,"week52Low":6.32,"pbRate":"-0.95","psRate":"6.22","week52High":12.58,"institutionHeld":0,"latestPrice":7.1,"eps":45.266125,"divideRate":0,"volume":38618,"delay":0,"ttmEps":45.266125,"open":7.73,"prevYearClose":8.78,"prevWeekClose":7.97,"prevMonthClose":7.78,"prevQuarterClose":7.55,"fiveDayClose":7.975,"twentyDayClose":7.15,"sixtyDayClose":6.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYNB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"KYNB","fiscalQuarterEnding":"2026/06","expectedEps":-3.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-4.68},{"market":"US","date":"2026-05-11","symbol":"KYNB","fiscalQuarterEnding":"2026/03","expectedEps":-3.36,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-3.74},{"market":"US","date":"2026-03-16","symbol":"KYNB","fiscalQuarterEnding":"2025/12","expectedEps":-3.89,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"post","actualEps":-3.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYNB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYNB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1783396800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYNB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYNB","date":"2026-09-16","current":0.15685,"percent":0.672515,"low":0.128311,"twenty":0.15062,"median":0.165893,"eighty":0.176251,"high":0.188982,"avg":0.163065,"sd":0.014969,"marketCap":31461693},"quantilePoints":[{"date":"2026-01-09","current":0.17821,"twenty":0.178998,"median":0.18018,"eighty":0.181362,"marketCap":38431727},{"date":"2026-01-16","current":0.170144,"twenty":0.170369,"median":0.172958,"eighty":0.17821,"marketCap":36692186},{"date":"2026-01-23","current":0.168268,"twenty":0.168268,"median":0.171269,"eighty":0.17821,"marketCap":36287641},{"date":"2026-01-30","current":0.150259,"twenty":0.160389,"median":0.169206,"eighty":0.172958,"marketCap":32404014},{"date":"2026-02-06","current":0.140692,"twenty":0.153073,"median":0.163953,"eighty":0.171457,"marketCap":30340837},{"date":"2026-02-13","current":0.140317,"twenty":0.147445,"median":0.160201,"eighty":0.171269,"marketCap":30259928},{"date":"2026-02-20","current":0.14707,"twenty":0.146282,"median":0.158795,"eighty":0.170369,"marketCap":31716288},{"date":"2026-02-27","current":0.13075,"twenty":0.144894,"median":0.154199,"eighty":0.170144,"marketCap":28196751},{"date":"2026-03-06","current":0.129155,"twenty":0.137315,"median":0.150635,"eighty":0.168643,"marketCap":27852888},{"date":"2026-03-13","current":0.131688,"twenty":0.133714,"median":0.147445,"eighty":0.165191,"marketCap":28399023},{"date":"2026-03-20","current":0.161033,"twenty":0.133301,"median":0.147633,"eighty":0.164047,"marketCap":29541837},{"date":"2026-03-27","current":0.144268,"twenty":0.133714,"median":0.1489,"eighty":0.163953,"marketCap":26466248},{"date":"2026-04-02","current":0.156621,"twenty":0.135327,"median":0.1489,"eighty":0.163094,"marketCap":28732471},{"date":"2026-04-10","current":0.158607,"twenty":0.13649,"median":0.150021,"eighty":0.161629,"marketCap":29096686},{"date":"2026-04-17","current":0.158607,"twenty":0.137128,"median":0.152651,"eighty":0.161629,"marketCap":29096686},{"date":"2026-04-24","current":0.154658,"twenty":0.137616,"median":0.154087,"eighty":0.16165,"marketCap":28372304},{"date":"2026-05-01","current":0.160371,"twenty":0.138929,"median":0.154658,"eighty":0.161209,"marketCap":29420432},{"date":"2026-05-08","current":0.156671,"twenty":0.140092,"median":0.155492,"eighty":0.161033,"marketCap":28741595},{"date":"2026-05-15","current":0.173439,"twenty":0.140542,"median":0.155518,"eighty":0.16165,"marketCap":28377265},{"date":"2026-05-22","current":0.171707,"twenty":0.141779,"median":0.155761,"eighty":0.163953,"marketCap":28093897},{"date":"2026-05-29","current":0.173687,"twenty":0.143209,"median":0.156128,"eighty":0.168258,"marketCap":28417746},{"date":"2026-06-05","current":0.168491,"twenty":0.144709,"median":0.156621,"eighty":0.168887,"marketCap":27567642},{"date":"2026-06-12","current":0.167254,"twenty":0.145601,"median":0.156867,"eighty":0.168639,"marketCap":27365237},{"date":"2026-06-18","current":0.170965,"twenty":0.145982,"median":0.157197,"eighty":0.169431,"marketCap":27972453},{"date":"2026-06-26","current":0.171707,"twenty":0.14617,"median":0.158138,"eighty":0.170144,"marketCap":28093897},{"date":"2026-07-02","current":0.1868,"twenty":0.14632,"median":0.158607,"eighty":0.170718,"marketCap":30563245},{"date":"2026-07-10","current":0.181109,"twenty":0.146883,"median":0.158743,"eighty":0.171457,"marketCap":29632179},{"date":"2026-07-17","current":0.182841,"twenty":0.14707,"median":0.160014,"eighty":0.171955,"marketCap":29915547},{"date":"2026-07-24","current":0.174924,"twenty":0.147445,"median":0.160711,"eighty":0.173192,"marketCap":28620151},{"date":"2026-07-31","current":0.167996,"twenty":0.147746,"median":0.161253,"eighty":0.173241,"marketCap":27486680},{"date":"2026-08-07","current":0.172709,"twenty":0.148684,"median":0.162522,"eighty":0.173005,"marketCap":28257845},{"date":"2026-08-14","current":0.174182,"twenty":0.14943,"median":0.163953,"eighty":0.173489,"marketCap":28498708},{"date":"2026-08-21","current":0.161795,"twenty":0.149739,"median":0.162522,"eighty":0.173439,"marketCap":29639587},{"date":"2026-08-28","current":0.176825,"twenty":0.149997,"median":0.163953,"eighty":0.174182,"marketCap":32392992},{"date":"2026-09-04","current":0.187656,"twenty":0.150217,"median":0.164422,"eighty":0.174924,"marketCap":34377062},{"date":"2026-09-11","current":0.176273,"twenty":0.150417,"median":0.165522,"eighty":0.175941,"marketCap":32291763},{"date":"2026-09-16","current":0.171742,"twenty":0.15062,"median":0.165893,"eighty":0.176251,"marketCap":31461693}],"updateTime":1789696094074},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYNB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668612029","title":"Kyntra Bio initiated with a Buy at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2668612029","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668612029?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:40","pubTimestamp":1789645210,"startTime":"0","endTime":"0","summary":"Lake Street initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $41 price target Published first on TheFly – the ultimate source for real...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyntra-bio-initiated-with-a-buy-at-lake-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyntra-bio-initiated-with-a-buy-at-lake-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666597228","title":"NASDAQ Trade Halt Volatility Trading Pause at 01:23 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2666597228","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666597228?lang=en_us&edition=fundamental","pubTime":"2026-09-11 01:23","pubTimestamp":1789061006,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 01:23 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nAQN2MIS29:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664533828","title":"Kyntra Bio Price Target Maintained with a $43.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2664533828","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664533828?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:36","pubTimestamp":1788258960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYNB/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885595","title":"Kyntra Bio Cuts Royalty Payments to NQ Project Phoebus for Accelerated Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885595","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664885595?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:37","pubTimestamp":1788212243,"startTime":"0","endTime":"0","summary":"Kyntra Bio  said late Monday it has amended its royalty financing deal with NQ Project Phoebus to reduce its payment obligations in exchange for an accelerated upfront payment.The biopharmaceutical company has lowered the maximum aggregate payments to $65 million from $125 million and made an accelerated upfront payment of $42.6 million, taking the total payments to $50 million.The remaining payments to NQ Project Phoebus, capped at $15 million, will be from 50% of the revenue received from Astellas in certain territories, the company said.As of June 30, the company said it had $53.1 million in cash, cash equivalents, investments, and accounts receivable, expected to fund operations into Q4 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885828","title":"Kyntra Bio Says FibroGen Europe Unit Settles Bankruptcy Obligations for About $0.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885828","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664885828?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:19","pubTimestamp":1788211152,"startTime":"0","endTime":"0","summary":"Kyntra Bio says FibroGen Europe unit settles bankruptcy obligations for about $0.1 millionKyntra Bio’s FibroGen Europe unit settled bankruptcy-related product development obligations and accrued inter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLlfRpD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930490.SGD","LU0784385840.USD","LU1003076772.USD","LU2237443622.USD","LU3187612489.SGD","LU0960981461.USD","LU0289739699.SGD","LU1481599808.USD","LU1487256676.USD","LU1989771016.USD","LU2125909593.SGD","LU0784385170.HKD","LU2539964713.USD","LU1829250122.USD","LU0757432116.USD","LU0203345920.USD","AZN.UK","LU0792757196.USD","LU0211328371.USD","LU0310800965.SGD","LU1051770623.HKD","LU1291159041.SGD","LU2433249047.HKD","LU0963555726.SGD","LU0122379950.USD","LU0545039389.USD","IE00BFTCPJ56.SGD","LU0784384876.USD","LU2125909247.SGD","LU1064927863.SGD","LU0011850046.USD","LU1923622614.USD","LU2112291526.USD","LU2293690249.USD","LU2237443382.USD","LU0266013472.USD","LU0997586515.USD","03165","LU0499090636.EUR","LU0972486137.USD","LU2237443549.SGD","LU0052756011.USD","LU1496350502.SGD","LU1003077747.HKD","SGXZ57979304.SGD","LU0077335932.USD","KYNB","BK4139","LU0949170772.SGD","LU0526926950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883217","title":"Kyntra Bio cuts max royalty cap to $65M from $125M, pays $42.6M upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883217","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883217?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:45","pubTimestamp":1788209107,"startTime":"0","endTime":"0","summary":"Kyntra Bio (KYNB) announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, materi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyntra-bio-cuts-max-royalty-cap-to-65m-from-125m-pays-42-6m-upfront-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyntra-bio-cuts-max-royalty-cap-to-65m-from-125m-pays-42-6m-upfront-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664888754","title":"Kyntra Bio, - Reduces Royalty Financing Payment Cap to $65 Mln from $125 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888754?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:11","pubTimestamp":1788207098,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887918","title":"Kyntra Bio, - Cash Runway Expected into Fourth Quarter of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887918?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:11","pubTimestamp":1788207098,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0UR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664588879","title":"Kyntra Bio, - Pro Forma Cash, Equivalents, Investments, Receivables $53.10 Mln as of June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2664588879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664588879?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:11","pubTimestamp":1788207098,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0UR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882578","title":"Kyntra Bio Prepays USD 42.6 Million Under Amended Royalty Financing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882578","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664882578?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:07","pubTimestamp":1788206860,"startTime":"0","endTime":"0","summary":"Kyntra Bio prepays USD 42.6 million under amended royalty financing dealKyntra Bio amended its royalty financing agreement with NQ Project Phoebus, cutting maximum aggregate payments to USD 65 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL1rmt93:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","BK4588","LU0314104364.USD","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","BK4112","BK4139","NDAQ","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BQXX3F31.USD","SG9999014005.SGD","BK4585","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","KYNB","LU2210149790.SGD","IE00BQXX3D17.EUR","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664888265","title":"Press Release: Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888265","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888265?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:05","pubTimestamp":1788206700,"startTime":"0","endTime":"0","summary":"-- Company reduces the maximum aggregate payments under its royalty. financing agreement from $125 million to $65 million. -- Company accelerated payment of $42.6 million upfront, bringing total. payments made to date to $50 million, a full return of NQ Project Phoebus,L.P.'s invested capital, with up to $15 million of additional. -- Remaining payments, capped at $15 million, to be paid from 50% of the. revenue received from Astellas in the Astellas territories excluding. -- Pro forma for the upfront payment, cash, cash equivalents, investments,and accounts receivable of $53.1 million as of June 30, 2026 Cash runway. Phoebus, L.P., bringing total payments made to date to $50 million, a. revenue Kyntra Bio receives from Astellas in the Astellas territories","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4604","BK4232","ADC","R","NETL","BK4588","BK4585","BK4555","KYNB","03160","BK4099","BK4231","BK4022","BK4080","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659014431","title":"Oppenheimer Keeps Their Buy Rating on Kyntra Bio (KYNB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659014431","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659014431?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:56","pubTimestamp":1786712193,"startTime":"0","endTime":"0","summary":"In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Kyntra Bio, with a price target of $35.00. According to TipRanks,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-keeps-their-buy-rating-on-kyntra-bio-kynb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-keeps-their-buy-rating-on-kyntra-bio-kynb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYNB","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186112","title":"Analysts Offer Insights on Healthcare Companies: Kyntra Bio (KYNB) and Minerva Neurosciences (NERV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659186112?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:00","pubTimestamp":1786698042,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kyntra Bio (KYNB) and Minerva Neurosciences (NERV). Kyntra Bio (K...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kyntra-bio-kynb-and-minerva-neurosciences-nerv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kyntra-bio-kynb-and-minerva-neurosciences-nerv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","HCSG","XBI","BK4581","LABU","KYNB","LU0128526141.USD","NERV","BK4588","BK4585","XLV","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659602921","title":"Kyntra Bio, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659602921","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659602921?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:02","pubTimestamp":1786654941,"startTime":"0","endTime":"0","summary":"Kyntra Bio, Inc. reports results for the quarter ended June 30 - Earnings SummaryKyntra Bio, Inc.KYNB.OQreported a quarterly adjusted loss of $4.69 per share for the quarter ended June 30, lower than ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A28Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659916760","title":"Kyntra Bio Posts Investor Presentation Highlighting FG-3246/fg-3180 Phase 2 Program in Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2659916760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659916760?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:23","pubTimestamp":1786652638,"startTime":"0","endTime":"0","summary":"Kyntra Bio posts investor presentation highlighting FG-3246/FG-3180 Phase 2 program in prostate cancerKyntra Bio highlighted Phase 2 enrollment for FG-3246 monotherapy in metastatic castration-resista","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL6YM2jf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162600","title":"Kyntra Bio Q2 EPS $2.96, Sales $(1.474M) Miss $2.007M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162600","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162600?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:06","pubTimestamp":1786651605,"startTime":"0","endTime":"0","summary":"Kyntra Bio Q2 EPS $2.96, Sales $(1.474M) Miss $2.007M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/KYNB","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kyntra Bio Q2 EPS $2.96, Sales $(1.474M) Miss $2.007M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659898162","title":"Kyntra Bio Q2 FY26 Returns to Profit at $12 Million; Revenue Turns to $(1.5) Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659898162","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659898162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:04","pubTimestamp":1786651478,"startTime":"0","endTime":"0","summary":"Kyntra Bio Q2 FY26 returns to profit at $12 million; revenue turns to $(1.5) millionKyntra Bio posted Q2 revenue of $(1.47) million, swinging from $1.35 million a year earlier.Net income from continui","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL5d1hfc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","LU2210150020.SGD","NDAQ","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","BK4585","KYNB","SG9999014005.SGD","BCDF","BK4112","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659416400","title":"Kyntra Bio Inc Q2 Net Income from Cont Ops USD 11.974 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659416400","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659416400?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:03","pubTimestamp":1786651380,"startTime":"0","endTime":"0","summary":"BRIEF-Kyntra Bio Inc Q2 Net Income From Cont Ops USD 11.974 MillionAug 13 (Reuters) - Kyntra Bio Inc Q2 net income USD 11.974 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX8QJ8PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659683162","title":"Press Release: Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659683162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659683162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651320,"startTime":"0","endTime":"0","summary":"-- Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody. prostate cancer , continues enrolling with interim analysis on. -- Phase 3 protocol of roxadustat for the treatment of anemia in patients. burden  has been finalized with the goal to initiate the. -- Additional data from the Phase 3 MATTERHORN study were presented at the. improvements in transfusion independence in patients with HTB and. -- Cash, cash equivalents, investments, and accounts receivable of $95.7. -- Kyntra Bio to host conference call and webcast presentation today at 5:00. first-in-class ADC targeting CD46 in mCRPC continues; interim analysis is. on track for the fourth quarter of 2026.Roxadustat-- Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia. in patients with LR-MDS and high transfusion burden  has been. -- In a post hoc analysis of the Phase 3 MATTERHORN study, patients. treated with roxadustat showed a clinically meaningful improvement. in transfusion independence ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","LU0211328371.USD","LU0052756011.USD","BK4231","DD","LU0128525689.USD","R","HTB","LU1267930227.SGD","BK4588","LU0310800965.SGD","BK4206","TM","BK4139","BK4585","03160","BK4555","BK4080","BK4099","BK4022","BK4504","LU2236285917.USD","LU1267930490.SGD","ADC","KYNB","LU0310799852.SGD","LU0211327993.USD","BK4604","BK4232","NETL","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945542","title":"Kyntra Bio, Inc. Expected to Post a Loss of $3.18 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945542","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945542?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:43","pubTimestamp":1786480986,"startTime":"0","endTime":"0","summary":"Kyntra Bio, Inc. <KYNB.OQ> expected to post a loss of $3.18 a share - Earnings PreviewKyntra Bio, Inc.KYNB.OQKYNB.Ois expected to  show a rise in quarterly revenue when it reports  results on August 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N448247:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}